Insys Therapeutics

Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients. Our focus is on the discovery, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.
Type
Public
HQ
Chandler, US
Founded
1998
Size (employees)
510 (est)
Insys Therapeutics was founded in 1998 and is headquartered in Chandler, US

Key People at Insys Therapeutics

Michael L. Babich

Michael L. Babich

CEO
Darryl S. Baker

Darryl S. Baker

CFO
Larry Dillaha

Larry Dillaha

CMO

Insys Therapeutics Office Locations

Insys Therapeutics has an office in Chandler
Chandler, US (HQ)
444 S Ellis Rd

Insys Therapeutics Metrics

Insys Therapeutics Financial Metrics

Revenue (2015)

$330.8 m

Revenue growth (2014-15), %

49%

Gross profit

$301.9 m

Gross profit margin (2015), %

91%

Net income (2015)

$58.5 m

Market capitalization (21-Mar-2017)

$719.9 m

Closing share price (21-Mar-2017)

$10.3

Cash (31-Dec-2015)

$79.5 m
Insys Therapeutics's current market capitalization is $719.9 m.
Insys Therapeutics's revenue was reported to be $330.8 m in FY, 2015 which is a 48.9% increase from the previous period.
FY, 2013FY, 2014FY, 2015

Revenue

$99.3 m$222.1 m$330.8 m

Revenue growth, %

124%49%

Cost of goods sold

$12.7 m$28.9 m

Gross profit

$86.6 m$199.5 m$301.9 m

Gross profit Margin, %

87%90%91%

Operating expense total

$54.1 m$135.5 m$209.5 m

EBIT

$32.6 m$64 m$92.4 m

EBIT margin, %

33%29%28%

Interest expense

$928 k

Interest income

$502 k

Pre tax profit

$31.6 m$93 m

Income tax expense

$8.8 m

Net Income

$40.4 m$38 m$58.5 m
FY, 2013FY, 2014FY, 2015

Cash

$45.4 m$58.1 m$79.5 m

Accounts Receivable

Inventories

$14.5 m$34.8 m$41.7 m

Current Assets

$82.2 m$151 m$253.2 m

PP&E

$10.1 m$38.4 m

Total Assets

$100.6 m$215.1 m$351.2 m

Accounts Payable

$16.6 m$27.5 m$36.4 m

Current Liabilities

$21.1 m$45.7 m$88.9 m

Common Stock

$354 k$719 k

Preferred Stock

Additional Paid-in Capital

$168.5 m$216.4 m$245.7 m

Retained Earnings

($89 m)($51.1 m)$7.4 m

Total Equity

$79.5 m$165.7 m$253.7 m

Financial Leverage

1.3 x1.3 x1.4 x
FY, 2013FY, 2014FY, 2015

Net Income

$40.4 m$58.5 m

Depreciation and Amortization

$1.8 m$2.5 m$5.3 m

Accounts Receivable

($13 m)($10 m)($22 m)

Inventories

($7.4 m)($20 m)($6.9 m)

Accounts Payable

Cash From Operating Activities

$24.2 m$49.7 m$100.9 m

Purchases of PP&E

($5.1 m)($22.2 m)($13.8 m)

Cash From Investing Activities

($5.5 m)($69.9 m)($88.7 m)

Cash From Financing Activities

$26.3 m$32.9 m$9.3 m

Income Taxes Paid

$991 k$3 m$15.4 m

Insys Therapeutics Market Value History

Insys Therapeutics Median Salaries

Source: 24 public H-1B filings from Insys Therapeutics

Insys Therapeutics News

Insys Therapeutics Company Life

You may also be interested in